Pfiz­er wins first US ap­proval for pen­tava­lent meningo­coc­cal vac­cine 

Pfiz­er on Fri­day won ap­proval for its next mass-mar­ket vac­cine, a pen­tava­lent meningo­coc­cal vac­cine cov­er­ing the most com­mon serogroups in­fect­ing chil­dren and young adults ages 10 to 25 years old.

The vac­cine, dubbed Pen­braya, com­bines the com­po­nents of Pfiz­er’s two cur­rent­ly ap­proved vac­cines Tru­men­ba and Ni­men­rix, to­geth­er cov­er­ing groups A, B, C, W and Y. Meningo­coc­cal dis­ease can cause menin­gi­tis, or in­flam­ma­tion of the brain and spinal cord mem­branes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER